News and Trends 7 Nov 2018 Belgian Biotech to Abandon Phase III Cell Therapy Trial for Bone Disease Bone Therapeutics is going to discontinue its cell therapy Phase III trial after finding little hope of success for patients with the bone disease osteonecrosis. If all had gone as planned, the full trial would have monitored 118 patients over 24 months. However, an interim analysis on 44 patients after 12 months found little evidence […] November 7, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2018 Solid Phase II Performance for French Autoimmune Liver Disease Drug Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […] November 7, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2018 First Potential Vaccine for Chikungunya Virus Flies Through Phase II The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […] November 6, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2018 Potential HIV Treatment Shows Early Stage Promise According to Phase I/IIa trial results from an Israeli biotech, an HIV drug reduced patients’ HIV levels by up to 99%, and might one day become a new treatment for the infection. The trial, run by Zion Medical, found that the synthetic peptide drug reduced the level of viral RNA in patients’ blood by up to […] November 6, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2018 Series C Bags German Company €17M for Irregular Heartbeat Treatment Omeicos Therapeutics has secured €17M in a Series C round to fund clinical development of its lead treatment for irregular heartbeat. Robert Fischer, CEO of the German biopharmaceutical company, told me that getting the attention of investors such as the Dutch company Forbion, which led the round, was just as helpful as the money itself. […] November 5, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2018 Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment, Oxabact, in patients with a rare genetic condition that causes kidney failure. The results came from an interim analysis one year into a three-year trial, where Oxthera is testing its gut microbiome treatment on patients with primary hyperoxaluria type […] November 2, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Nov 2018 This Biotech Uses Metal Alloys to Reshape Your Bones We venture up to the North European climes of Finland this week. In the city of Espoo, Synoste is developing bone lengthening devices made of smart malleable materials. Mission: To modernize bone lengthening devices with new techniques such as using malleable metals with wireless control. People born with discrepancies in limb length often suffer from […] November 2, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2018 Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the handful of European biotechs worth €1B or more. The new money might help with the marketing and manufacture of Strimvelis, an EMA-approved gene therapy for […] November 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2018 Forget Daily Pills: HIV Could Be Treated With Monthly Injections A monthly antiviral injection may be as good as daily HIV drugs for suppressing infections, reports the British biotech ViiV Healthcare. This could make the treatment of HIV easier for patients and improve compliance. In the first five months of a Phase IIb trial, the company gave 274 HIV-infected adults three daily oral antiretrovirals. After […] October 31, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2018 Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […] October 31, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 30 Oct 2018 British Diagnostics Firm Develops More Accurate Fetal Health Screen A lab kit from British diagnostics company Angle could make non-invasive fetal health screens more accurate by analyzing whole fetal cells in the mother’s blood. To screen your unborn baby for genetic conditions, the most accurate current option is invasive techniques such as amniocentesis. These techniques take samples directly from the womb that contain fetal […] October 30, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2018 Tree Bark Could be a Sustainable Source of Adhesives and Sugars Researchers at the Technical Research Centre of Finland are making it easier to process spare tree bark into useful resins and sugars. In Finland, three million tonnes of bark is produced from softwood trees such as firs and pines, and, despite its potential as a source of industrial products, a lot is thrown away. “Bark […] October 29, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email